633 related articles for article (PubMed ID: 32683985)
1. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative.
Warner JJ; Crook HL; Whelan KM; Bleser WK; Roiland RA; Hamilton Lopez M; Saunders RS; Wang TY; Hernandez AF; McClellan MB; Califf RM; Brown N;
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006606. PubMed ID: 32683985
[TBL] [Abstract][Full Text] [Related]
2. Advancing Value-Based Models for Heart Failure: A Call to Action From the Value in Healthcare Initiative's Value-Based Models Learning Collaborative.
Joynt Maddox K; Bleser WK; Crook HL; Nelson AJ; Hamilton Lopez M; Saunders RS; McClellan MB; Brown N;
Circ Cardiovasc Qual Outcomes; 2020 May; 13(5):e006483. PubMed ID: 32393125
[TBL] [Abstract][Full Text] [Related]
3. Value in Healthcare Initiative: Summary and Key Recommendations.
Joynt Maddox KE; Bleser WK; Das SR; Desai NR; Ng-Osorio J; O'Brien E; Psotka MA; Wadhera RK; Weintraub WS; Konig M
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006612. PubMed ID: 32683984
[TBL] [Abstract][Full Text] [Related]
4. Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative's Prior Authorization Learning Collaborative.
Psotka MA; Singletary EA; Bleser WK; Roiland RA; Hamilton Lopez M; Saunders RS; Wang TY; McClellan MB; Brown N;
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006564. PubMed ID: 32683983
[TBL] [Abstract][Full Text] [Related]
5. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
Newell S; Jordan Z
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
[TBL] [Abstract][Full Text] [Related]
6. Frontiers of Upstream Stroke Prevention and Reduced Stroke Inequity Through Predicting, Preventing, and Managing Hypertension and Atrial Fibrillation: A Call to Action From the Value in Healthcare Initiative's Predict & Prevent Learning Collaborative.
Bufalino VJ; Bleser WK; Singletary EA; Granger BB; O'Brien EC; Elkind MSV; Hamilton Lopez M; Saunders RS; McClellan MB; Brown N;
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006780. PubMed ID: 32683982
[TBL] [Abstract][Full Text] [Related]
7. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
8. Generating comparative evidence on new drugs and devices after approval.
Cipriani A; Ioannidis JPA; Rothwell PM; Glasziou P; Li T; Hernandez AF; Tomlinson A; Simes J; Naci H
Lancet; 2020 Mar; 395(10228):998-1010. PubMed ID: 32199487
[TBL] [Abstract][Full Text] [Related]
9. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
10. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
[TBL] [Abstract][Full Text] [Related]
11. Generating comparative evidence on new drugs and devices before approval.
Naci H; Salcher-Konrad M; Kesselheim AS; Wieseler B; Rochaix L; Redberg RF; Salanti G; Jackson E; Garner S; Stroup TS; Cipriani A
Lancet; 2020 Mar; 395(10228):986-997. PubMed ID: 32199486
[TBL] [Abstract][Full Text] [Related]
12. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association.
McClellan M; Brown N; Califf RM; Warner JJ
Circulation; 2019 Feb; 139(9):e44-e54. PubMed ID: 30674212
[TBL] [Abstract][Full Text] [Related]
13. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice.
Willke RJ; Crown W; Del Aguila M; Cziraky MJ; Khan ZM; Migliori R
Value Health; 2013; 16(6 Suppl):S10-5. PubMed ID: 24034306
[TBL] [Abstract][Full Text] [Related]
14. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
15. Patient engagement in clinical trials: The Clinical Trials Transformation Initiative's leadership from theory to practical implementation.
Patrick-Lake B
Clin Trials; 2018 Feb; 15(1_suppl):19-22. PubMed ID: 29452519
[TBL] [Abstract][Full Text] [Related]
16. Challenges encountered in the conduct of Optimal Health: A patient-centered comparative effectiveness study of interventions for adults with serious mental illness.
Kogan JN; Schuster J; Nikolajski C; Schake P; Carney T; Morton SC; Kang C; Reynolds CF
Clin Trials; 2017 Feb; 14(1):5-16. PubMed ID: 27681658
[TBL] [Abstract][Full Text] [Related]
17. Sex Disparities in Cardiovascular Device Evaluations: Strategies for Recruitment and Retention of Female Patients in Clinical Device Trials.
Ghare MI; Chandrasekhar J; Mehran R; Ng V; Grines C; Lansky A
JACC Cardiovasc Interv; 2019 Feb; 12(3):301-308. PubMed ID: 30732736
[TBL] [Abstract][Full Text] [Related]
18. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
